Valuation: Sanofi

Market Cap 85.63B 97.24B 81.13B 73.24B 138B 9,323B 140B 971B 374B 4,766B 365B 357B 15,281B P/E 2026 *
11.4x
P/E 2027 * 9.92x
Enterprise Value 97.09B 110B 91.99B 83.05B 157B 10,571B 159B 1,101B 424B 5,404B 414B 405B 17,326B EV / Sales 2026 *
2.04x
EV / Sales 2027 * 1.86x
Free-Float
88.34%
Yield 2026 *
5.95%
Yield 2027 * 6.29%
1 day+2.32%
1 week-1.01%
Current month-5.69%
1 month-5.69%
3 months-4.16%
6 months-10.81%
Current year-12.63%
1 week 70.97
Extreme 70.97
74.25
1 month 70.97
Extreme 70.97
78.1
Current year 70.92
Extreme 70.9227
84.93
1 year 70.92
Extreme 70.9227
91.06
3 years 70.92
Extreme 70.9227
110.84
5 years 70.92
Extreme 70.9227
110.84
10 years 62.99
Extreme 62.99
110.84
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer - 2026-08-31
Director TitleAgeSince
Director/Board Member 61 2019-04-29
Director/Board Member 56 2020-04-27
Director/Board Member 65 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
+1.57%-1.01% - - 97.03B
+0.22%+2.52%+54.64%+119.20% 1,056B
-0.04%-0.75%+44.07%+72.18% 645B
+0.21%-0.54%+13.87%+77.85% 465B
-1.59%-1.00%+74.67%+42.95% 368B
-0.06%-3.88%+34.32%+40.74% 335B
-0.79%+2.01%+19.82%+28.48% 275B
-1.19%-1.21%+9.82%+12.15% 255B
+0.00%+4.16%+49.89%+58.83% 229B
-0.51%-0.90%+35.14%+102.44% 188B
Average -0.08%+0.12%+37.36%+61.65% 423.98B
Weighted average by Cap. -0.12%+0.30%+41.29%+73.83%

Financials

2026 *2027 *
Net sales 47.65B 54.11B 45.15B 40.76B 76.82B 5,188B 77.81B 540B 208B 2,652B 203B 199B 8,503B 50.64B 57.51B 47.98B 43.32B 81.65B 5,514B 82.7B 574B 221B 2,819B 216B 211B 9,038B
Net income 7.48B 8.49B 7.09B 6.4B 12.06B 814B 12.21B 84.78B 32.62B 416B 31.89B 31.19B 1,335B 8.89B 10.09B 8.42B 7.6B 14.33B 968B 14.51B 101B 38.76B 495B 37.89B 37.06B 1,586B
Net Debt 11.46B 13.02B 10.86B 9.81B 18.48B 1,248B 18.72B 130B 50.01B 638B 48.88B 47.81B 2,046B 8.34B 9.47B 7.9B 7.13B 13.44B 908B 13.61B 94.49B 36.36B 464B 35.55B 34.77B 1,488B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Date Price Change Volume
26-09-30 €72.45 +1.57% 5
26-09-29 €71.47 -0.18% 398,872
26-09-28 €71.60 -0.40% 1,254,407
26-09-25 €71.89 -1.39% 2,014,268
26-09-24 €72.90 -0.39% 139,607
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
71.47EUR
Average target price
94.06EUR
Spread / Average Target
+31.61%

Quarterly revenue - Rate of surprise